A
CRNX icon

AlphaQuest’s Crinetics Pharmaceuticals CRNX Stock Holding History

AlphaQuest’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,844
Closed -$738K – 484
2025
Q4 		$738K Buy
15,844
+1,136
+8% +$50.6K 0.04% 583
2025
Q3 		$613K Sell
14,708
-13,087
-47% -$418K 0.04% 669
2025
Q2 		$799K Buy
+27,795
New +$858K 0.08% 385
2025
Q1 		– Sell
-107
Closed -$5.47K – 2034
2024
Q4 		$5.47K Buy
107
+94
+723% +$5.26K ﹤0.01% 1576
2024
Q3 		$664 Sell
13
-921
-99% -$47.5K ﹤0.01% 1664
2024
Q2 		$41.8K Buy
+934
New +$43.1K 0.01% 1098

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

AlphaQuest's CRNX Position: Q1 2026 in Review

AlphaQuest sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2026, closing a stake of 15,844 shares — an estimated $738K sold.

AlphaQuest first reported a position in CRNX in Q2 2024 and held it in 6 quarters. The position peaked at $799K in Q2 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • AlphaQuest reported no remaining Crinetics Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 15,844 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $738K.
  • AlphaQuest first reported a position in Crinetics Pharmaceuticals in Q2 2024 and held it in 6 quarters.
  • AlphaQuest's Crinetics Pharmaceuticals position peaked at $799K in Q2 2025.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.